Are U.S. organizations involved in the development and commercialization of phage technology?
Yes. The American Society for Microbiology (ASM) and many university researchers are following developments in phage technology very closely. Many concerns have embarked upon efforts to discover commercial applications, either by themselves or as part of international concerns. Q: Why was phage therapy abandoned during the 20th century in favor of antibiotics – and why is it more acceptable today? A: When western concerns first engaged in widespread attempts to commercialize phage treatments in the 1920s, scientific knowledge about phages and phage therapy was minimal. In fact, scientists had not conclusively determined that phages were a living organism (instead of an enzyme) until 1942. This confusion regarding the very essence of phages led to significant problems in the production of effective phage therapies. Scientists did not understand how precise the match between specific phages and their bacterial targets had to be in order for phage therapy to work. As a result, many early
Related Questions
- What shall be the possible ways of commercialization if the technology is not in final product form but under development?
- Can they offer management service for science and new technology development and commercialization?
- Are U.S. organizations involved in the development and commercialization of phage technology?
